ClinicalTrials.gg
RecruitingNCT06493708EMBODIERUpdated Feb 25, 2026

Effectiveness of EMDR in Borderline Personality Disorder

An interventional study of Trauma focused psychotherapy: EMDR in Borderline Personality Disorder, sponsored by Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Oct 2024; still recruiting 2 years 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Borderline personality disorder (BPD) is a severe mental disorder characterized by four major symptomatological domains: interpersonal instability, perceptive and identity disorders, emotional and behavioural dysregulation. Considering a multifactorial etiological model, it has been suggested that the interaction between behavioral, environmental and genetic factors may promote the development of BPD. Early life stress events (ELS) in childhood and adolescence are highly prevalent in this population and constitute an environmental risk factor for the development of BPD. This correlates with the fact that Post-traumatic Stress Disorder (PTSD) is frequently comorbid in BPD leading to more severe symptoms and worse psychosocial functioning. At the therapeutic level, the treatment of BPD is an open challenge as psychotherapeutic interventions are of limited effectiveness and characterized by high drop-out rates. Eye Movement Desensitization and Reprocessing (EMDR) is the gold standard for treating PTSD. However, scientific evidence on the application of EMDR in patients with BPD is limited. This study aims to assess the feasibility and effectiveness of an EMDR protocol on the nuclear symptomatology of BPD (emotional and behavioral dysregulation) in a group of DBP patients with/without PTSD comorbidity, through a systematic assessment of the peculiar dimensions of the disorder. The basic hypothesis is that EMDR, through a short-term intervention, can act both on the traumatic PTSD-like experiences reported by patients and on the clinical manifestations peculiar to DBP, in particular by improving the emotional regulation capacity of patients with BPD.

02

Conditions studied

  • Borderline Personality Disorder
03

In context

Borderline Personality Disorder

278 studies on the registry are indexed under Borderline Personality Disorder; 70 are open to participants now.

This study's planned enrollment of 56 is below the median of 70 across 221 interventional studies indexed under Borderline Personality Disorder.

Browse Borderline Personality Disorder studies →

Lead sponsor

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia is the lead sponsor of 84 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be over 18 years old
  • A current diagnosis of PBD according to the was confirmed using the SCID-5-CV and SCID-5-PD diagnostic scale

Exclusion criteria

Exclusion Criteria:

  • Suicidal ideation in the last 3 months (suicidal thoughts active intentionally but without specific planning or suicidal thoughts active with planning and intentionality)
  • Intellectual disability
  • Any active disturbance from use of substances or alcohol
  • Any other diagnosis of Axis I, except for Depressive Disorders, Anxious Spectrum Disorders, Obsessive-Compulsive Disorder.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Participant)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    EMDR intervention

    14 sessions of psychotherapy with EMDR will be carried out with patients. One session per week, lasting 90 minutes. The first two sessions will be used for the description of the EMDR method and for stabilization, then there will be treatment sessions.

    Other: Trauma focused psychotherapy: EMDR

  • No intervention
    Waiting List

    Treatment as usual

Interventions

  • OtherTrauma focused psychotherapy: EMDR

    14 sessions of psychotherapy with EMDR will be carried out with patients. One session per week, lasting 90 minutes. The first two sessions will be used for the description of the EMDR method and for stabilization, then there will be treatment sessions.

06

What researchers measure

Primary outcomes

  1. Core symptoms of BPD

    The primary outcome is the improvement of the core symptoms of BPD, measured by the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD). The scale ranges from 0 to 36, with higher scores indicating greater severity.

    Time frame: 4 timepoints: baseline (T0), after 6 (T6), 12 (T12), 18 (T18) weeks

Secondary outcomes

  1. Self perception of BPD symptoms

    Self perception of BPD symptoms measured by the Borderline Symptom List 23 (BSL-23). The scale ranges from 0 to 4, with higher scores indicating greater severity.

    Time frame: 4 timepoints: baseline (T0), after 6 (T6), 12 (T12), 18 (T18) weeks

Other outcomes

  1. Emotion disregulation

    Emotion disregulation measured by the Difficulties in emotion regulation scale (DERS-36). The scale ranges from 36 to 180, with higher scores indicating greater difficulties in emotion regulation.

    Time frame: 4 timepoints: baseline (T0), after 6 (T6), 12 (T12), 18 (T18) weeks

  2. Ruminative thinking

    Ruminative thinking measured by the Rumination Response Scale (RRS). The scale ranges from 22 to 88, with higher scores indicating greater rumination.

    Time frame: 4 timepoints: baseline (T0), after 6 (T6), 12 (T12), 18 (T18) weeks

  3. Dissociative symptoms

    Dissociative symptoms measured by the Dissociative Experiences Scale (DES). The scale ranges from 0 to 100, with higher scores indicating greater dissociative experiences.

    Time frame: 4 timepoints: baseline (T0), after 6 (T6), 12 (T12), 18 (T18) weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06493708
Lead sponsor
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Responsible party
Antonio Vita (Prof, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia) — Principal investigator
First posted
Jul 10, 2024
Start date
Oct 1, 2024
Primary completion
May 31, 2026 (estimated)
Completion
Oct 1, 2026 (estimated)
Last update
Feb 25, 2026

Study contacts

Alessandra Minelli, Prof
Contact
alessandra.minelli@unibs.it
+39 380 3503413
Stefano Barlati, Prof
Contact
stefano.barlati@unibs.it
+39 338 2027373l
Alessandra Minelli, Prof
principal investigator · Università degli Studi di Brescia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion